Results for tag: "Prenatal DNA Sequencing"

Prenatal DNA sequencing is a biotechnological process that enables the detection of genetic anomalies in a fetus by analyzing small fragments of DNA that are circulating in the mother's blood. This non-invasive test, often referred to as non-invasive prenatal testing (NIPT), can be performed to screen for a variety of genetic disorders, such as Down syndrome, Edwards syndrome, and Patau syndrome, among others. Technological advancements have improved the accuracy and reliability of prenatal testing, broadening the spectrum of detectable conditions. The application of next-generation sequencing technology has been a key factor in driving the growth of the prenatal DNA sequencing market. This market has emerged as a specialized segment within the broader field of genetic testing, focusing on the challenges and ethical considerations unique to prenatal screening. Companies in this space offer a range of services, from basic chromosomal analysis to more extensive genetic profiling, catering to different medical needs and preferences of expectant parents. Among the key players in the prenatal DNA sequencing market are companies such as Illumina, Inc., which provides genetic sequencing technology and NIPT solutions; Berry Genomics, offering a variety of prenatal testing options; and Natera, Inc., which specializes in cell-free DNA testing, including its own proprietary prenatal tests. Sequenom Laboratories, a subsidiary of LabCorp, is another renowned entity recognized for its developments in non-invasive prenatal screening. Additionally, BGI Genomics and Agilent Technologies are notable for their contributions to advancing prenatal genetic testing and Show Less Read more